Novel N-methyl-d-aspartate receptor antagonists: a review of compounds patented since 2006

Bibliography

• Paoletti P, Neyton J. NMDA receptor subunits: function and pharmacology. Curr Opin Pharmacol 2007;7:39-47
   PubMed Web of Science ®Google Scholar
• Yang CR, Svensson KA. Allosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: the therapeutic potentials for schizophrenia. Pharmacol Ther 2008;120:317-32
   PubMed Web of Science ®Google Scholar
• Henson MA, Roberts AC, Perez-Otano I, Philpot BD. Influence of the NR3A subunit on NMDA receptor functions. Prog Neurobiol 2010;91:23-37
   PubMed Web of Science ®Google Scholar
• Paoletti P, Ascher P, Neyton J. High-affinity zinc inhibition of NMDA NR1-NR2A receptors. J Neurosci 1997;17:5711-25
   PubMed Web of Science ®Google Scholar
• Perin-Dureau F, Rachline J, Neyton J, Paoletti P. Mapping the binding sites of the neuroprotectant ifenprodil on NMDA receptors. J Neurosci 2002;22:5955-65
   PubMed Web of Science ®Google Scholar
• Mugnaini M. Allosteric interactions at the NMDA receptor channel complex. In: Bowery NG, editor, Allosteric Receptor Modulation in Drug Targeting 2006;93:93-134
   Google Scholar
• Tang LH, Aizenman E. The modulation of N-methyl-D-aspartate receptors by redox and alkylating reagents in rat cortical neurons in vitro. J Physiol 1995;465:303-23
   Google Scholar
• Choi YB, Tenneti L, Le DA, Molecular basis of NMDA receptor-coupled ion channel modulation by S-nitrosylation. Nat Neurosci 2000;3:15-21
   PubMed Web of Science ®Google Scholar
• Hardingham GE, Fukunaga Y, Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci 2002;5:405-14
   PubMed Web of Science ®Google Scholar
• Pittenger C, Sanacora G, Krystal JH. The NMDA receptor as a therapeutic target in major depressive disorder. CNS Neurol Dis Drug Targ 2007;6:101-15
   PubMedGoogle Scholar
• Nagy J, Horvath C, Farkas S, NR2B subunit selective NMDA antagonists inhibit neurotoxic effect of alcohol-withdrawal in primary cultures of rat cortical neurons. Neurochem Int 2004;44:17-23
   PubMed Web of Science ®Google Scholar
• Robbins TW, Murphy ER. Behavioural pharmacology: 40+ years of progress, with a focus on glutamate receptors and cognition. Trends Pharm Sci 2006;27:141-8
   PubMed Web of Science ®Google Scholar
• Olney JW. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995;52:998-1007
   PubMed Web of Science ®Google Scholar
• Lindsley CW, Shipe WD, Wolkenberg SE, Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia. Curr Top Med Chem 2006;6:771-85
   PubMed Web of Science ®Google Scholar
• Ikonomidou C, Turksi L. Why did NMDA antagonists fail clinical trials for stroke and traumatic brain injury? Lancet Neurol 2002;1:383-6
   PubMed Web of Science ®Google Scholar
• Mony L, Kew NCJ, Gunthorpe JM, Paoletti P. Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential. Br J Pharmacol 2009;157:1301-17
   PubMed Web of Science ®Google Scholar
• McKeage K. Memantine: a review of its use in moderate to severe Alzheimer's disease. CNS Drugs 2009;23:881-97
   PubMed Web of Science ®Google Scholar
• Chang HR, Kuo CC. Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor. J Med Chem 2008;51:1534-45
   Google Scholar
• Siu A, Drachtman R. Dextromethorphan: a review of N-methyl-D-aspartate receptor antagonist in the management of pain. CNS Drug Rev 2007;13(1):96-106
   Google Scholar
• Parsons CG, Stoffler A, Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system – too little activation is bad, too much is even worse. Neuropharmacology 2007;53:699-723
   PubMed Web of Science ®Google Scholar
• Liu S, Lam FW, Sciamanna SF, Diamondoid derivatives possessing therapeutic activity in the treatment of neurologic disorders. US2008009546; 2008
   Google Scholar
• Balestra M, Bernstein P, Ernst G, Ethanamine compounds and their use for treating depression. WO2010074647; 2010
   Google Scholar
• Monyer H, Burnashev N, Laurie DJ, Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 1994;12:529-40
   PubMed Web of Science ®Google Scholar
• Zhou M, Baudry M. Developmental changes in NMDA neurotoxicity reflect developmental changes in subunit composition of NMDA receptors. J Neurosci 2006;26:2956-63
   PubMed Web of Science ®Google Scholar
• Borza I, Domany G. NR2B selective NMDA antagonists: the evolution of the ifenprodil-type pharmacophore. Curr Topics Med Chem 2006;6:687-95
   PubMedGoogle Scholar
• Borza I, Horvath C, Farkas S, New 4-benyzlidene-piperidine derivatives. WO2006010964; 2006
   Google Scholar
• Borza I, Horvath C, Farkas S, Indole-2-carboxamidine derivatives as NMDA receptor antagonists. WO2006010965; 2006
   Google Scholar
• Borza I, Bartane Szalai G, Bozo E, New benzoyl urea derivatives. WO2006010966; 2006
   Google Scholar
• Borza I, Horvath C, Farkas S, Kynurenic acid amide derivatives as NR2B receptor antagonists. WO2006010967; 2006
   Google Scholar
• Keseru G, Vago I, Farkas S, New aryloxy acetic acid amide derivatives. WO2006010968; 2006
   Google Scholar
• Borza I, Horvath C, Farkas S, New heterocyclic carboxylic acid amide derivatives. WO2006010969; 2006
   Google Scholar
• Borza I, Kolok S, Gyorgyi IS, Indole-2-carboxamidines as novel NR2B selective NMDA receptor antagonists. Bioorg Med Chem Lett 2005;15:5439-41
   Google Scholar
• Layton ME, Rodzinak KJ, Kelly MJ III, Sanderson PE. 1,3-disubstituted heteroaryl NMDA/NR2B antagonists. WO2006017409; 2006
   Google Scholar
• Layton ME, Rodzinak KJ, Kelly MJ III, Sanderson PE. N-Alkyl-azacycloalkyl NMDA/NR2B antagonists. WO2006113471; 2006
   Google Scholar
• Traynelis SF, Dingledine RJ, Liotta DC. Improved selection of pH dependent compounds for in vivo therapy. WO2006023957; 2006
   Google Scholar
• Liotta DC, Snyder JP, Traynelis SF, NMDA receptor antagonists for neuroprotection. WO2009006437; 2009
   Google Scholar
• Dingledine RJ, Traynelis SF; Liotta DC. Methods of identifying safe NMDA receptor antagonists. WO2009061935; 2009
   Google Scholar
• Mott DD, Doherty JJ, Wahsburn MS, Phenylethanolamines inhibit NMDA receptors by enhancing proton inhibition. Nat Neurosci 1998;1:659-67
   PubMed Web of Science ®Google Scholar
• Dingledine RJ, Traynelis SF, Liotta DC, Snyder JP. PH dependent NMDA receptor antagonists. WO2002072542; 2002
   Google Scholar
• Tahirovic EA, Geballe M, Gruszecka-Kowalik E, Enantiomeric propanolamines as selective N-methyl-D-aspartate 2B receptor antagonists. J Med Chem 2008;51:5506-21
   Web of Science ®Google Scholar
• Mosley CA, Myers SJ, Murray EE, Synthesis, structural activity-relationships, and biological evaluation of novel amide-based allosteric binding site antagonists in NR1A/NR2B N-methyl-D-aspartate receptors. Bioorg Med Chem 2009;17:6463-80
   Google Scholar
• Dingledine RJ, Traynelis SF. NMDA receptor antagonists for the treatment of neuropsychiatric disorders. WO2009137843; 2009
   Google Scholar
• Johnson JW, Asher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 1987;325:529-31
   PubMed Web of Science ®Google Scholar
• Hawkinson EJ, Huber RK, Sahota SP, The N-methyl-D-aspartate (NMDA) receptor glycine site antagonist ACEA 1021 does not produce pathological changes in rat brain. Brain Res 1997;744:227-34
   PubMed Web of Science ®Google Scholar
• Bristow JL, Landon L, Saywell LK, Tricklebank DM. The glycine/NMDA receptor antagonist L-701324 reverses isolation-induced deficits in prepulse inhibition in rat. Psychopharmacol 1995;118:230-2
   PubMedGoogle Scholar
• Bristow LJ, Hutson PH, Thorn L, Tricklebank MD. The glycine/NMDA receptor antagonist, R-(+)-HA966, blocks activation of the mesolimbic dopaminergic system induced by phencyclidine and dizocilpine (MK-801) in rodents. Br J Pharmacol 1993;108:1156-63
   Google Scholar
• Wallace MS, Rowbothan MC, Katz NP, A randomized, double-blind, placebo-controlled trail of a glycine antagonist in neuropathic pain. Neurology 2002;59:1694-700
   PubMed Web of Science ®Google Scholar
• Henrich M, Bauer A, Nagal J, Glycine B antagonists. WO2010037533; 2010
   Google Scholar
• Khan A, Moskal J, Wood P. NMDA receptor modulators and uses thereof. WO2010033757; 2010
   Google Scholar
• Shim SS, Hammonds MD, Kee BS. Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site. Eur Arch Psychiatry Clin Neurosci 2008;258:16-27
   PubMed Web of Science ®Google Scholar
• Moskal JR, Kuo AG, Weiss C, GLYX-13: a monoclonal antibody-derived peptide that acts as an N-methyl-D-aspartate receptor modulator. Neuropharmacology 2005;49:1077-87
   PubMed Web of Science ®Google Scholar
• Zhang X, Sullivan JA, Moskal JR, Stanton PK. A NMDA receptor glycine site partial agonist, GLYX-13, simultaneously enhances LTP and reduces LTD at Schaffer collateral-CA1 synapses in hippocampus. Neuropharmacology 2008;55:1238-50
   PubMed Web of Science ®Google Scholar
• Kemp A, Manahan-Vaughan D. Hippocampal long-term depression: master or minion in declarative memory processes? Trends Neurosci 2007;30:111-18
   Google Scholar
• Martynyuk AE, Dennis DM, Gravenstein M, Methods and materials for treating mental illness. WO2006020171; 2006
   Google Scholar
• Yarotskyy V, Glushakov AV, Sumners C, Differential modulation of glutamatergic transmission by 3,5-dibromo-L-phenylalanine. Mol Pharmacol 2005;67:1648-54
   Google Scholar
• Cao W, Shah HP, Glushakov AV, Efficacy of 3,5-dibromo-L-phenylalanine in rat models of stroke, seizures and sensorimotor gating deficits. Br J Pharmacol 2009;158:2005-13
   Google Scholar
• Ip NY, Zhu HJ, Ip FC. Oxazolidine derivatives as NMDA antagonists. WO2009092324; 2009
   Google Scholar
• Moloney GP, Iskander MN, Craik DJ. Stability studies of oxazolidine-based compounds using 1H-NMR spectroscopy. J Pharm Sci 2010;99:3362-71
   Google Scholar
• Gant TG, Sarshar S. Substituted cyclohexanones. US20080268071; 2008
   Google Scholar
• Gant TG. Adamantane modulators of NMDA receptor and/or 5HT3 receptor. WO2010060037; 2010
   Google Scholar
• Tung R. Morphinan compounds. WO2008137474; 2008
   Google Scholar
• Graham PB, Silverman IR. Morphinan compounds. WO20100033801; 2010
   Google Scholar
• Masse CE, Persichetti RA. Propanediol-dicarbamate derivatives. WO2009129181; 2009
   Google Scholar
• Watkins JC. Some chemical highlights in the development of excitatory amino acid pharmacology. Can J Pharmacol 1991;69:1064-75
   Google Scholar
• Childers EW. EAA-090. Drugs Fut 2002;27:633-8
   Google Scholar
• Baudy RB. Derivatives of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl]phosphonic acid and methods of making them. US20060079679; 2006
   Google Scholar
• Brandt RM, Cummons AT, Potestio L, Effects of the N-methyl-D-aspartate receptor antagonist perzinfotel [EAA-090; [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-e-2-yl)-ethylphosphonic acid]] on chemically induced thermal hypersensitivity. Pharmacol Exp Ther 2005;313:1379-86
   Google Scholar
• Eppler CM, Muir WW III, Hustead DR, Composition and methods employing NMDA antagonists for achieving an anesthetic-sparing effect. WO2009029618; 2009
   Google Scholar
• Fultz TJ, Wang Y. Therapeutic conjugates and methods of using them. WO2007065036; 2007
   Google Scholar
• Sobrio F, Gilbert G, Perrio C, PET and SPECT imaging of the NMDA receptor system: An overview of radiotracer development. Mini-Rev Med Chem 2010;10:870-86
   Google Scholar
• Robins EG, Arstad E. Imaging 18F or 11C-labelled alkylthiophenyl guanidines. WO2006136846; 2006
   Google Scholar
• Robins GE, Zhao Y, Khan I, Synthesis and in vitro evaluation of 18F-labelled S-fluoroalkyl diarylguanidines: novel high-affinity NMDA receptor antagonists for imaging with PET. Bioorg Med Chem Lett 2010;20:1749-51
   PubMedGoogle Scholar
• Arstad E, Henriksen G. In vivo imaging compounds. WO2007063286; 2007
   Google Scholar
• Claiborne CF, McCauley JA, Libby BE, Orally efficacious NR2B-selective NMDA receptor antagonists. Bioorg Med Chem Lett 2003;13:697-700
   PubMedGoogle Scholar
• Grant KA, Colombo G, Grant J, Rogawski MA. Dizocilpine-like discriminative stimulus effects of low-affinity uncompetitive NMDA antagonists. Neuropharmacology 1996;35:1709-19
   PubMed Web of Science ®Google Scholar
• Lipton SA. Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond. Nat Rev 2006;5:160-70
   Google Scholar
• Xia P, Chen HV, Zhang D, Lipton SA. Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses. J Neurosci 2010;30:11246-50
   PubMed Web of Science ®Google Scholar
• Goff DC, Herz L, Posever T, A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology 2005;179:144-50
   PubMed Web of Science ®Google Scholar
• Sablin S, Bachurin S, Beznosko B, Fluroro-containing derivatives of hydrogenated pyrido[4,3-b]indoles with neuroprotective and cognition enhancing properties, process for preparing, and use. WO2009038764; 2009
   Google Scholar
• Grigor'ev VV, Dranyi OA, Bachurin SO. Comparative study of action mechanism of dimebon and memantine on AMPA- and NMDA-subtypes glutamate receptors in rat cerebral neurons. Bull Exp Biol Med 2003;136:474-7
   Google Scholar
• Chen M, Lu TJ, Chen XJ, Differential roles of NMDA receptor subtypes in ischemic neuronal cell death and ischemic tolerance. Stroke 2008;39:3042-8
   PubMed Web of Science ®Google Scholar
• Wang YT, Liu Y, Wong TP, Liu L. Neuroprotective modulation of NMDA receptor subtype activities. WO2007006157; 2007
   Google Scholar
• Buller AL, Larson HC, Schneider BE, The molecular basis of NMDA receptor subtypes: Native receptor diversity is predicted by subunit composition. J Neurosci 1994;14:5471-84
   PubMed Web of Science ®Google Scholar
• Wyllie DJA, Behe P, Colquhoun D. Single-channel activations and concentration jumps: comparison of recombinant NR1a/NR2A and NR1a/NR2D NMDA receptors. J Physiol 1998;510.1:1-18
   Google Scholar
• Feng B, Tse HW, Skifter DA, Structure-activity analysis of a novel NR2C/NR2D-preferring NMDA receptor antagonist: 1-(phenanthrene-2-carbonyl)piperazine-2,3-dicarboxylic acid. Br J Pharmacol 2004;141:508-16
   Google Scholar
• Mosley CA, Acker TM, Hansen KB, Quinazolin-4-one derivatives: a novel class of noncompetitive NR2C/D subunit-selective N-methyl-D-aspartate receptor antagonist. J Med Chem 2010;53:5476-90
   PubMed Web of Science ®Google Scholar
• Yao Y, Mayer ML. Characterization of a soluble ligand binding domain of the NMDA receptor regulatory subunit NR3A. J Neurosci 2006;26:4559-66
   Google Scholar
• Aarts MM, Tymianski M. Novel treatment of excitotoxicity: targeted disruption of intracellular signalling from glutamate receptors. Biochem Pharmacol 2003;66:877-86
   Google Scholar
• Aarts M, Liu Y, Liu L, Treatment of ischemic brain damage by perturbing NMDA receptor-PSD-95 protein interactions. Science 2002;298:846-50
   PubMed Web of Science ®Google Scholar
• Gurd J, Dykstra C, Tymianski M. Treatment for epilepsy. WO2009140416; 2009
   Google Scholar
• Bach A, Stromgaard K. Modified peptides as potent inhibitors of the PSD-95/NMDA receptor interaction. WO2010004003; 2010
   Google Scholar
• Tasker A, Coucette T, Tymianski M, Treatment for anxiety. WO2009006548; 2009
   Google Scholar
• Cui H, Hayashi A, Sun HS, PDZ protein interactions underlying NMDA receptor-mediated excitotoxicity and neuroprotection by PSD-95 inhibitors. J Neurosci 2007;27:9901-15
   PubMed Web of Science ®Google Scholar